Abstract
The present study was performed to investigate the therapeutic potential of β- Carotene against STZ induced diabetes by using in vivo and in vitro models. MTT assay was performed to check the cytotoxic effect of β- Carotene in HepG2 liver cells which were treated with β- Carotene (10, 20 μM). The anti-diabetic activity was examined by estimating different enzymes in cell lines. Further, we validated activity by using in vitro models. Male Albino Wistar rats were divided into five groups each group contain six animals (n = 6). The diabetes was induced via intraperitoneal injection of STZ and the β- Carotene was treated with daily doses of 10 and 20 mg/kg for 14 days. After the last dose of β- Carotene, rats were sacrificed and the biochemical parameters were estimated in liver homogenate. The disease control group showed an elevation in the level of cytokine as well as ROS and β- Carotene-treated animals showed a reduction in the level of cytokine and normal content of anti-oxidant enzyme in liver tissue homogenate. We found β- Carotene had no toxic effect on HepG2 liver cells. In the case of the glucose utilization assay, it was found that glucose uptake level was significantly increased with the increasing concentrations of β-Carotene. In conclusion β- Carotene improves glucose metabolism along with oxidative status in STZ-induced diabetic rats.